Accelr8 Shares up 60 Percent on MRSA Dx Patent Allowance | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Accelr8 were up more than 60 percent this afternoon after the company said the US Patent and Trademark Office gave it a notice of allowance on the first patent related to its diagnostic platform.
 
Shares in the company were up 1.36 at $3.82 in late-afternoon trading today.
 
The company said the methods covered by the patent will enable its BACcel system to "quickly identify major multiple-drug-resistant bacteria and their resistance mechanisms."
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.